Centrum Badawcze Panaceum Agnieszka Brzezicka Magdalena Lenkiewicz Sp. z o.o.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The centre is conducting studies that target established cardiovascular disease, high cardiovascular risk, and hypertension. Trials aim to test novel agents that may lower cardiovascular events and improve blood‑pressure control.
- Evaluation of a novel peptide therapy for cardiovascular death reduction
- Comparison of weekly insulin‑based regimen on cardiovascular outcomes
- Assessment of lipid‑lowering RNA therapy in severe hypertriglyceridemia
With 25 active trials and a team of 11 investigators, Centrum Badawcze Panaceum is a key hub for cardiovascular innovation in Poland.
Digestive System Diseases
Research includes participants with idiopathic or diabetic gastroparesis. The goal is to determine whether a new oral agent can improve stomach emptying and symptom relief.
- Phase 2 study of a pro‑kinetic compound in gastroparesis
- Real‑world evaluation of mobility impact in patients with gastroparesis
The site leverages its clinical infrastructure to generate evidence for digestive health therapies.
Immune System Diseases
A broad portfolio focuses on Sjögren’s syndrome, systemic lupus erythematosus, and ulcerative colitis. Trials assess biologic agents that aim to reduce systemic inflammation and improve patient‑reported outcomes.
- Study of HZN‑1116 in moderate‑to‑severe Sjögren’s syndrome
- Evaluation of litifilimab for active systemic lupus erythematosus
- Long‑term safety of efavaleukin alfa in ulcerative colitis
These investigations reflect the centre’s commitment to advancing immune‑mediated disease treatments.
Musculoskeletal Diseases
The facility is evaluating therapies for knee osteoarthritis and related functional outcomes. One study measures how a topical anti‑inflammatory gel influences daily activity levels using wearable trackers.
- Real‑world evidence study of Voltaren gel on mobility
- Assessment of physical activity changes in osteoarthritis patients
By integrating digital health tools, the site explores both symptom relief and quality‑of‑life improvements.
Nutritional and Metabolic Diseases
Ongoing work targets type 2 diabetes, hypertriglyceridemia, and severe hypertriglyceridemia. Trials test RNA‑based therapies and peptide inhibitors designed to lower triglyceride levels and stabilize glycemic control.
- Plozasiran trials in hypertriglyceridemia populations
- Comparison of weekly IcoSema versus daily insulin regimens
- Zilebesiran study for hypertension and cardiovascular risk
The research aligns with the centre’s focus on metabolic risk reduction and patient safety.
Skin and Connective Tissue Diseases
Investigations include atopic dermatitis, chronic urticaria, prurigo nodularis, hidradenitis suppurativa, and discoid lupus erythematosus. The primary aim is to evaluate new topical or systemic agents that can achieve clearer skin and lessen disease burden.
- Ruxolitinib cream efficacy in prurigo nodularis
- Methotrexate versus placebo in moderate‑to‑severe atopic dermatitis
- Eltrekibart trial for moderate‑to‑severe hidradenitis suppurativa
- Daxdilimab study in primary discoid lupus erythematosus
- BP11 versus Xolair in chronic spontaneous urticaria
These studies illustrate the centre’s dedication to improving dermatologic outcomes for diverse patient groups.
Immune System Phenomena
Research emphasizes the underlying immune system phenomena that drive autoimmunity. Projects investigate how novel biologics modulate immune signaling pathways in diseases such as Sjögren’s syndrome and lupus.
- Mechanistic assessment of dazodalibep on systemic manifestations of Sjögren’s syndrome
- Biomarker analysis in litifilimab-treated systemic lupus erythematosus
By focusing on pathophysiological mechanisms, the site contributes to the scientific understanding of immune dysregulation.
Immune System Processes
Trials target specific immune system processes such as cytokine inhibition and B‑cell modulation. The goal is to determine whether targeted interference can achieve disease remission with favorable safety profiles.
- Evaluation of tibulizumab for hidradenitis suppurativa lesions
- Zasocitinib study in moderate‑to‑severe hidradenitis suppurativa
- Efavaleukin alfa investigation in ulcerative colitis
The centre’s integrated approach bridges basic immunology with clinical outcome measurement.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 15 of 27 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1Amgen Inc.1active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.5trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum Badawcze Panaceum Agnieszka Brzezicka Magdalena Lenkiewicz Sp. z o.o.
lock Showing 1 of 34 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 40-week study comparing the efficacy, safety and patient-reported outcomes of once weekly IcoSema and once or twice daily insulin degludec/insulin aspart 100 units/mL, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily pre-mixed insulin. COMBINE 5 | Novo Nordisk A/S | Phase III | Not Recruiting | — | Dec 2025 |
IMP list
lock Showing 1 of 27 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dazodalibep | 3 | Unknown | 2024-06-07 | 2025-05-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.